z-logo
Premium
Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney
Author(s) -
Van Der Giet Markus,
Khattab Mohammed,
Börgel Jan,
Schlüter Hartmut,
Zidek Walter
Publication year - 1997
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0701074
Subject(s) - ppads , suramin , purinergic receptor , adenosine , endocrinology , medicine , vasodilation , chemistry , p2 receptor , stimulation , adenosine receptor , receptor , pharmacology , biology , agonist , biochemistry
The activation of various purinoceptors in rat renal vasculature by P 1 ,P 2 ‐diadenosine pyrophosphate (Ap 2 A), P 1 ,P 3 ‐diadenosine triphosphate (Ap 3 A), P 1 ,P 4 ‐diadenosine tetraphosphate (Ap 4 A), P 1 ,P 5 ‐diadenosine pentaphosphate (Ap 5 A), P 1 ,P 6 ‐diadenosine hexaphosphate (Ap 6 A) was studied by measuring their effects of perfusion pressure of a rat isolated perfused kidney. The vasoconstrictive response to Ap 5 A was completely due to P 2X purinoceptor activation, that to Ap 4 A and Ap 6 was P 2X purinoceptor mediated to a large extent, as evidenced by the inhibitory effects of suramin and pyridoxal‐phosphate‐6‐azophenyl‐2′,4′‐disulphonic acid tetrasodium (PPADS). The vasoconstrictive effects of Ap 2 A and Ap 3 A were mostly due to stimulation of A 1 ‐receptors, as shown by the inhibitory effect of 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX). The vasoconstrictive response to Ap 6 A was partially insensitive to A 1 and P 2X purinoceptor blockers. In raised tone preparations Ap 2 A and Ap 3 A evoked vasodilatation, which was blocked by the A 2 receptor blocker, 3,7‐dimethyl‐1‐propargylxanthine (DMPX). In raised tone preparations Ap 4 A evoked vasodilatation when the P 2 ‐purinoceptors were blocked by suramin. The activation of different purinoceptor subtypes by diadenosine phosphates critically depends on the number of phosphate groups.British Journal of Pharmacology (1997) 120 , 1453–1460; doi: 10.1038/sj.bjp.0701074

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom